<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="abolish">
<roleset id="abolish.01" name="" wordnet="1">
<roles>
  <role n="0" descr="causer/agent 			 	// change at molecular level //
"/>
  <role n="1" descr="entity abolished 			// normal transcription, normal splicing //
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
This intronic mutation, which segregates in a dominant and fully penetrant manner over three generations, abolishes normal LHX4 splicing and activates two exonic cryptic splice sites, thereby predicting two different proteins deleted in their homeodomain sequence.

</text>
       <arg n="0">This intronic mutation
</arg>
       <arg n="1">normal LHX4 splicing
</arg>
<fdg>
         1	This	this	det:&gt;3	@DN&gt; %&gt;N DET DEM SG
         2	intronic	intronic	attr:&gt;3	@A&gt; %&gt;N &lt;?&gt; A ABS
         3	mutation	mutation	subj:&gt;18	@SUBJ %NH N NOM SG
         4	,	,
         5	which	which	subj:&gt;6	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
         6	segregates	segregate	mod:&gt;3	@+FMAINV %VA V PRES SG3
         7	in	in	loc:&gt;6	@ADVL %EH PREP
         8	a	a	det:&gt;9	@DN&gt; %&gt;N DET SG
         9	dominant	dominant	pcomp:&gt;7	@&lt;P %NH A ABS
         10	and	and		@CC %CC CC
         11	fully	fully	ad:&gt;12	@AD-A&gt; %E&gt; ADV
         12	penetrant	penetrant	attr:&gt;13	@A&gt; %&gt;N A ABS
         13	manner	manner		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@&lt;P %NH N NOM SG
         14	over	over	mod:&gt;13	@&lt;NOM %N&lt; PREP
         15	three	three	qn:&gt;16	@QN&gt; %&gt;N NUM CARD
         16	generations	generation	pcomp:&gt;14	@&lt;P %NH N NOM PL
         17	,	,
         18	abolishes	abolish		@+FMAINV %VA V PRES SG3
         19	normal	normal	attr:&gt;20	@A&gt; %&gt;N A ABS
         20	LHX4	lhx4	attr:&gt;21	@A&gt; %&gt;N N NOM SG
         21	splicing	splicing	obj:&gt;18	@OBJ %NH N NOM SG
         22	and	and	cc:&gt;18	@CC %CC CC
         23	activates	activate	cc:&gt;18	@+FMAINV %VA V PRES SG3
         24	two	two	qn:&gt;28	@QN&gt; %&gt;N NUM CARD
         25	exonic	exonic	attr:&gt;26	@A&gt; %&gt;N &lt;?&gt; A ABS
         26	cryptic	cryptic	attr:&gt;27	@A&gt; %&gt;N A ABS
         27	splice	splice	attr:&gt;28	@A&gt; %&gt;N N NOM SG
         28	sites	site	obj:&gt;23	@OBJ %NH N NOM PL
         29	,	,
         30	thereby	thereby		@ADVL %EH ADV	@AD-A&gt; %E&gt; ADV
         31	predicting	predict		@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING	@A&gt; %&gt;N A ABS	@APP %NH A ABS	@SUBJ %NH A ABS	@OBJ %NH A ABS	@&lt;P %NH A ABS	@&lt;NOM %N&lt; A ABS	@NH %NH A ABS
         32	two	two	qn:&gt;34	@QN&gt; %&gt;N NUM CARD
         33	different	different	attr:&gt;34	@A&gt; %&gt;N A ABS
         34	proteins	protein		@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL	@APP %NH N NOM PL	@&lt;P %NH N NOM PL
         35	deleted	delete		@+FMAINV %VA V PAST
         36	in	in	loc:&gt;35	@ADVL %EH PREP
         37	their	they	attr:&gt;38	@A&gt; %&gt;N PRON PERS GEN PL3
         38	homeodomain	homeodomain	attr:&gt;39	@A&gt; %&gt;N &lt;?&gt; N NOM SG
         39	sequence	sequence	pcomp:&gt;36	@&lt;P %NH N NOM SG
         40	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
Patient 1 has a G-to-A transition at the first nucleotide of intron 2, which abolishes normal splicing.

</text>
       <arg n="0">a G-to-A transition at the first nucleotide of intron 2
</arg>
       <arg n="1">normal splicing
</arg>
<fdg>
         1	Patient	patient	attr:&gt;2	@A&gt; %&gt;N A ABS
         2	1	1	subj:&gt;3	@SUBJ %NH NUM CARD
         3	has	have	main:&gt;0	@+FMAINV %VA V PRES SG3
         4	a	a	det:&gt;6	@DN&gt; %&gt;N DET SG
         5	G-to-A	g-to-a	attr:&gt;6	@A&gt; %&gt;N N NOM SG
         6	transition	transition	obj:&gt;3	@OBJ %NH N NOM SG
         7	at	at	loc:&gt;3	@ADVL %EH PREP
         8	the	the	det:&gt;10	@DN&gt; %&gt;N DET
         9	first	first	attr:&gt;10	@A&gt; %&gt;N NUM ORD
         10	nucleotide	nucleotide	pcomp:&gt;7	@&lt;P %NH N NOM SG
         11	of	of	mod:&gt;10	@&lt;NOM-OF %N&lt; PREP
         12	intron	intron	attr:&gt;13	@A&gt; %&gt;N N NOM SG
         13	2	2	pcomp:&gt;11	@&lt;P %NH NUM CARD
         14	,	,
         15	which	which	subj:&gt;16	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
         16	abolishes	abolish	mod:&gt;13	@+FMAINV %VA V PRES SG3
         17	normal	normal	attr:&gt;18	@A&gt; %&gt;N A ABS
         18	splicing	splicing	obj:&gt;16	@OBJ %NH N NOM SG
         19	.     .
</fdg>
</example>
<example src="MEDLINE" no="3">
<text>
Determining the complete exon-intron structure of JAG1 allowed detailed mutational analysis of DNA samples from non-deletion AGS patients, revealing three frame-shift mutations, two splice donor mutations and one mutation abolishing RNA expression from the altered allele.

</text>
       <arg n="0">one mutation
</arg>
       <arg n="1">RNA expression
</arg>
<fdg>
         1	Determining	determine	subj:&gt;8	@-FMAINV %VA ING
         2	the	the	det:&gt;5	@DN&gt; %&gt;N DET
         3	complete	complete	attr:&gt;4	@A&gt; %&gt;N A ABS
         4	exon-intron	exon-#intron	attr:&gt;5	@A&gt; %&gt;N N NOM SG
         5	structure	structure	obj:&gt;1	@OBJ %NH N NOM SG
         6	of	of	mod:&gt;5	@&lt;NOM-OF %N&lt; PREP
         7	JAG1	jag1	pcomp:&gt;6	@&lt;P %NH N NOM SG
         8	allowed	allow	main:&gt;0	@+FMAINV %VA V PAST
         9	detailed	detailed	attr:&gt;10	@A&gt; %&gt;N A ABS
         10	mutational	mutational	attr:&gt;11	@A&gt; %&gt;N A ABS
         11	analysis	analysis	obj:&gt;8	@OBJ %NH N NOM SG
         12	of	of	mod:&gt;11	@&lt;NOM-OF %N&lt; PREP
         13	DNA	dna		@A&gt; %&gt;N ABBR NOM SG	@&lt;P %NH ABBR NOM SG
         14	samples	sample		@+FMAINV %VA V PRES SG3	@SUBJ %NH N NOM PL	@&lt;P %NH N NOM PL
         15	from	from		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
         16	non-deletion	non-deletion	attr:&gt;17	@A&gt; %&gt;N &lt;?&gt; A ABS
         17	AGS	ags	attr:&gt;18	@A&gt; %&gt;N N NOM SG
         18	patients	patient	pcomp:&gt;15	@&lt;P %NH N NOM PL
         19	,	,
         20	revealing	reveal	mod:&gt;18	@-FMAINV %VA ING
         21	three	three	qn:&gt;23	@QN&gt; %&gt;N NUM CARD
         22	frame-shift	frame-shift	attr:&gt;23	@A&gt; %&gt;N &lt;?&gt; N NOM SG
         23	mutations	mutation	obj:&gt;20	@OBJ %NH N NOM PL
         24	,	,
         25	two	two	qn:&gt;28	@QN&gt; %&gt;N NUM CARD
         26	splice	splice	attr:&gt;27	@A&gt; %&gt;N N NOM SG
         27	donor	donor	attr:&gt;28	@A&gt; %&gt;N N NOM SG
         28	mutations	mutation		@NH %NH N NOM PL	@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL	@APP %NH N NOM PL	@&lt;P %NH N NOM PL
         29	and	and	cc:&gt;28	@CC %CC CC
         30	one	one	qn:&gt;31	@QN&gt; %&gt;N NUM CARD
         31	mutation	mutation	cc:&gt;28	@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
         32	abolishing	abolish		@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING	@A&gt; %&gt;N A ABS	@APP %NH A ABS	@OBJ %NH A ABS	@&lt;P %NH A ABS	@&lt;NOM %N&lt; A ABS	@NH %NH A ABS
         33	RNA	rna	attr:&gt;34	@A&gt; %&gt;N ABBR NOM SG
         34	expression	expression		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
         35	from	from	mod:&gt;34	@&lt;NOM %N&lt; PREP
         36	the	the	det:&gt;38	@DN&gt; %&gt;N DET
         37	altered	altered	attr:&gt;38	@A&gt; %&gt;N A ABS
         38	allele	allele	pcomp:&gt;35	@&lt;P %NH N NOM SG
         39	.     .
</fdg>
</example>
<example src="MEDLINE" no="4">
<text>
Linomide and antibody-targeted superantigen therapy abolishes formation of liver metastases in mice.

</text>
       <arg n="0">Linomide and antibody-targeted superantigen therapy 
</arg>
       <arg n="1">formation of liver metastases in mice
</arg>
<fdg>
1	Linomide	linomide	cc:&gt;5	@SUBJ %NH &lt;?&gt; N NOM SG
2	and	and	cc:&gt;5	@CC %CC CC
3	antibody-targeted	antibody-targeted	attr:&gt;4	@A&gt; %&gt;N &lt;?&gt; A ABS
4	superantigen	superantigen	attr:&gt;5	@A&gt; %&gt;N &lt;?&gt; N NOM SG
5	therapy	therapy	subj:&gt;6	@SUBJ %NH N NOM SG
6	abolishes	abolish	main:&gt;0	@+FMAINV %VA V PRES SG3
7	formation	formation	obj:&gt;6	@OBJ %NH N NOM SG
8	of	of	mod:&gt;7	@&lt;NOM-OF %N&lt; PREP
9	liver	liver	attr:&gt;10	@A&gt; %&gt;N N NOM SG
10	metastases	metastasis	pcomp:&gt;8	@&lt;P %NH N NOM PL
11	in	in	mod:&gt;10	@&lt;NOM %N&lt; PREP
12	mice	mouse	pcomp:&gt;11	@&lt;P %NH N NOM PL
13	.     .
</fdg>
</example>
<example src="MEDLINE" no="5">
<text>
However, this complete removal of FabD from the crude FAS did not abolish its BCFA biosynthesis, but only reduced the level to 50-60% of the control level for acyl-CoA primer and to 80% for alpha-keto-beta-methylvalerate primer.

</text>
       <arg n="0">this complete removal of FabD from the crude FAS
</arg>
       <arg n="1">its BCFA biosynthesis
</arg>
       <arg n="M-NEG">not
</arg>
<fdg>

1	However	however	meta:&gt;14	@ADVL %EH ADV WH
2	,	,
3	this	this	det:&gt;5	@DN&gt; %&gt;N DET DEM SG
4	complete	complete	attr:&gt;5	@A&gt; %&gt;N A ABS
5	removal	removal	subj:&gt;12	@SUBJ %NH N NOM SG
6	of	of	mod:&gt;5	@&lt;NOM-OF %N&lt; PREP
7	FabD	fabd	pcomp:&gt;6	@&lt;P %NH N NOM SG
8	from	from	mod:&gt;7	@&lt;NOM %N&lt; PREP
9	the	the	det:&gt;11	@DN&gt; %&gt;N DET
10	crude	crude	attr:&gt;11	@A&gt; %&gt;N A ABS
11	FAS	fa	pcomp:&gt;8	@&lt;P %NH N NOM PL
12	did	do	v-ch:&gt;14	@+FAUXV %AUX V PAST
13	not	not	neg:&gt;12	@ADVL %EH NEG-PART
14	abolish	abolish	main:&gt;0	@-FMAINV %VA V INF
15	its	it	attr:&gt;16	@A&gt; %&gt;N PRON GEN SG3
16	BCFA	bcfa	attr:&gt;17	@A&gt; %&gt;N N NOM SG
17	biosynthesis	biosynthesis	obj:&gt;14	@OBJ %NH N NOM SG
18	,	,
19	but	but	cc:&gt;14	@CC %CC CC
20	only	only	meta:&gt;21	@ADVL %EH ADV
21	reduced	reduce	cc:&gt;14	@+FMAINV %VA V PAST
22	the	the	det:&gt;23	@DN&gt; %&gt;N DET
23	level	level	obj:&gt;21	@OBJ %NH N NOM SG
24	to	to	goa:&gt;21	@ADVL %EH PREP
25	50-60	50-60		@QN&gt; %&gt;N &lt;?&gt; NUM CARD
26	%	%	pcomp:&gt;24	@&lt;P %NH N NOM SG
27	of	of	mod:&gt;26	@&lt;NOM-OF %N&lt; PREP
28	the	the	det:&gt;30	@DN&gt; %&gt;N DET
29	control	control	attr:&gt;30	@A&gt; %&gt;N N NOM SG
30	level	level	pcomp:&gt;27	@&lt;P %NH N NOM SG
31	for	for	mod:&gt;30	@&lt;NOM %N&lt; PREP
32	acyl-CoA	acyl-coa	attr:&gt;33	@A&gt; %&gt;N &lt;?&gt; N NOM SG
33	primer	primer	pcomp:&gt;31	@&lt;P %NH N NOM SG
34	and	and	cc:&gt;31	@CC %CC CC
35	to	to	cc:&gt;31	@ADVL %EH PREP
36	80%	80%	pcomp:&gt;35	@&lt;P %NH NUM CARD
37	for	for	mod:&gt;36	@&lt;NOM %N&lt; PREP
38	alpha-keto-beta-methylvalerate	alpha-keto-beta-methylvalerate	attr:&gt;39	@A&gt; %&gt;N &lt;?&gt; N NOM SG
39	primer	primer	pcomp:&gt;37	@&lt;P %NH N NOM SG
40	.     .
</fdg>
</example>
<example src="MEDLINE" no="6">
<text>
Our results showed that co-administered DM was able to abolish completely the CPP effect induced by morphine, but had no effect on morphine-induced behavioral sensitization.

</text>
       <arg n="0">co-administered DM
</arg>
       <arg n="1">the CPP effect
</arg>
<fdg>
1	Our	we	attr:&gt;2	@A&gt; %&gt;N PRON PERS GEN PL1
2	results	result	subj:&gt;3	@SUBJ %NH N NOM PL
3	showed	show	main:&gt;0	@+FMAINV %VA V PAST
4	that	that	pm:&gt;7	@CS %CS CS
5	co-administered	co-administered	attr:&gt;6	@A&gt; %&gt;N A ABS
6	DM	dm	subj:&gt;7	@SUBJ %NH ABBR NOM SG	@SUBJ %NH ABBR NOM
7	was	be	obj:&gt;3	@+FMAINV %VA V PAST
8	able	able	comp:&gt;7	@PCOMPL-S %NH A ABS
9	to	to	pm:&gt;10	@INFMARK&gt; %AUX INFMARK&gt;
10	abolish	abolish	mod:&gt;8	@-FMAINV %VA V INF
11	completely	completely	man:&gt;10	@ADVL %EH ADV
12	the	the	det:&gt;14	@DN&gt; %&gt;N DET
13	CPP	cpp	attr:&gt;14	@A&gt; %&gt;N ABBR NOM SG
14	effect	effect	obj:&gt;10	@OBJ %NH N NOM SG
15	induced	induce	mod:&gt;14	@-FMAINV %VP EN
16	by	by	ha:&gt;15	@ADVL %EH PREP
17	morphine	morphine	pcomp:&gt;16	@&lt;P %NH N NOM SG
18	,	,
19	but	but	cc:&gt;7	@CC %CC CC
20	had	have	cc:&gt;7	@+FMAINV %VA V PAST
21	no	no	det:&gt;22	@DN&gt; %&gt;N DET
22	effect	effect	obj:&gt;20	@OBJ %NH N NOM SG
23	on	on	mod:&gt;22	@&lt;NOM %N&lt; PREP
24	morphine-induced	morphine-induced	attr:&gt;25	@A&gt; %&gt;N A ABS
25	behavioral	behavioral	attr:&gt;26	@A&gt; %&gt;N A ABS
26	sensitization	sensitization	pcomp:&gt;23	@&lt;P %NH N NOM SG
27	.     .
</fdg>
</example>
<example src="EMBO" no="1">
<text>
Noticeably, transcription at the rrn PC promoter by NEP-2 is completely abolished if CDF2-B can not bind to the template, as obtained by the mutation M1 (Figure 4A, compare lanes 1 and 4; Figure 4C, compare Wt and M1).

</text>
       <arg n="0">-
</arg>
       <arg n="1">transcription at the rrn PC promoter by NEP-2
</arg>
<fdg>
1	Noticeably	noticeably		@ADVL %EH ADV
2	,	,
3	transcription	transcription	subj:&gt;11	@SUBJ %NH N NOM SG
4	at	at	mod:&gt;3	@&lt;NOM %N&lt; PREP
5	the	the	det:&gt;8	@DN&gt; %&gt;N DET
6	rrn	rrn	attr:&gt;7	@A&gt; %&gt;N &lt;?&gt; N NOM SG
7	PC	pc	attr:&gt;8	@A&gt; %&gt;N ABBR NOM SG
8	promoter	promoter	pcomp:&gt;4	@&lt;P %NH N NOM SG
9	by	by	mod:&gt;8	@&lt;NOM %N&lt; PREP
10	NEP-2	nep-2	pcomp:&gt;9	@&lt;P %NH N NOM SG
11	is	be	v-ch:&gt;13	@+FAUXV %AUX V PRES SG3
12	completely	completely	meta:&gt;13	@ADVL %EH ADV
13	abolished	abolish		@-FMAINV %VP EN
14	if	if	pm:&gt;18	@CS %CS CS
15	CDF2-B	cdf2-b	subj:&gt;16	@SUBJ %NH &lt;?&gt; N NOM SG
16	can	can	v-ch:&gt;18	@+FAUXV %AUX V AUXMOD
17	not	not	neg:&gt;16	@ADVL %EH NEG-PART
18	bind	bind	cnd:&gt;13	@-FMAINV %VA V INF
19	to	to	ha:&gt;18	@ADVL %EH PREP
20	the	the	det:&gt;21	@DN&gt; %&gt;N DET
21	template	template	pcomp:&gt;19	@&lt;P %NH N NOM SG
22	,	,
23	as	as	pm:&gt;24	@CS %CS CS
24	obtained	obtain		@-FMAINV %VP EN
25	by	by	ha:&gt;24	@ADVL %EH PREP
26	the	the		@DN&gt; %&gt;N DET
27	mutation	mutation	attr:&gt;28	@A&gt; %&gt;N N NOM SG
28	M1	m1		@OBJ %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@&lt;P %NH ABBR NOM SG
29	(	(
30	Figure	figure	attr:&gt;31	@A&gt; %&gt;N N NOM SG
31	4A	4a		@APP %NH NUM CARD
32	,	,
33	compare	compare		@+FMAINV %VA V PRES	@-FMAINV %VA V INF	@&lt;P-FMAINV %VA V INF
34	lanes	lane	obj:&gt;33	@OBJ %NH N NOM PL
35	1	1	mod:&gt;34	@&lt;NOM %N&lt; NUM CARD
36	and	and	cc:&gt;35	@CC %CC CC
37	4	4	cc:&gt;35	@&lt;NOM %N&lt; NUM CARD
38	;	;
39	Figure	figure	attr:&gt;40	@A&gt; %&gt;N N NOM SG
40	4C	4c		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@APP %NH NUM CARD
41	,	,
42	compare	compare		@+FMAINV %VA V PRES	@-FMAINV %VA V INF	@&lt;P-FMAINV %VA V INF
43	Wt	wt	obj:&gt;42	@OBJ %NH ABBR NOM SG
44	and	and	cc:&gt;43	@CC %CC CC
45	M1	m1	cc:&gt;43	@OBJ %NH ABBR NOM SG
46	)	)
47	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
The A/T-rich mut sequence indicates the mutations introduced to abolish the A/T-rich element.

</text>
       <arg n="0">the mutations 
</arg>
       <arg n="1">the A/T-rich element
</arg>
<fdg>
1	The	the	det:&gt;4	@DN&gt; %&gt;N DET
2	A/T-rich	a/t-rich	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	mut	mut	attr:&gt;4	@A&gt; %&gt;N &lt;?&gt; N NOM SG
4	sequence	sequence	subj:&gt;5	@SUBJ %NH N NOM SG
5	indicates	indicate	main:&gt;0	@+FMAINV %VA V PRES SG3
6	the	the	det:&gt;7	@DN&gt; %&gt;N DET
7	mutations	mutation	subj:&gt;8	@SUBJ %NH N NOM PL
8	introduced	introduce	obj:&gt;5	@+FMAINV %VA V PAST
9	to	to	pm:&gt;10	@INFMARK&gt; %AUX INFMARK&gt;
10	abolish	abolish	obj:&gt;8	@-FMAINV %VA V INF
11	the	the	det:&gt;13	@DN&gt; %&gt;N DET
12	A/T-rich	a/t-rich	attr:&gt;13	@A&gt; %&gt;N N NOM SG
13	element	element	obj:&gt;10	@OBJ %NH N NOM SG
14	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
Mutation of the proximal GATA element in the context of the &amp;#8211;700 or the &amp;#8211;135 bp promoter completely abolished synergy, indicating that this element is essential for MEF2 &amp;#8211;GATA-4 cooperation. 

</text>
       <arg n="0">Mutation of the proximal GATA element in the context of the &amp;#8211;700 or the &amp;#8211;135 bp   
</arg>
       <arg n="1">synergy
</arg>
       <arg n="M-ADV">completely
</arg>
<fdg>
1	Mutation	mutation		@NH %NH N NOM SG	@SUBJ %NH N NOM SG
2	of	of	mod:&gt;1	@&lt;NOM-OF %N&lt; PREP
3	the	the	det:&gt;6	@DN&gt; %&gt;N DET
4	proximal	proximal	attr:&gt;5	@A&gt; %&gt;N A ABS
5	GATA	gata	attr:&gt;6	@A&gt; %&gt;N N NOM SG
6	element	element	pcomp:&gt;2	@&lt;P %NH N NOM SG
7	in	in	mod:&gt;6	@&lt;NOM %N&lt; PREP
8	the	the	det:&gt;9	@DN&gt; %&gt;N DET
9	context	context	pcomp:&gt;7	@&lt;P %NH N NOM SG
10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
11	the	the		@DN&gt; %&gt;N DET
12	&amp;#8211;	&amp;#8211;		@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
13	700	700		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@PCOMPL-S %NH NUM CARD	@&lt;P %NH NUM CARD	@QN&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
14	or	or		@CC %CC CC
15	the	the		@DN&gt; %&gt;N DET
16	&amp;#8211;	&amp;#8211;		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG	@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
17	135	135		@NH %NH NUM CARD	@OBJ %NH NUM CARD	@PCOMPL-S %NH NUM CARD	@&lt;P %NH NUM CARD	@QN&gt; %&gt;N NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
18	bp	bp	attr:&gt;19	@A&gt; %&gt;N ABBR NOM SG
19	promoter	promoter		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG	@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
20	completely	completely	ad:&gt;21	@AD-A&gt; %E&gt; ADV
21	abolished	abolished	attr:&gt;22	@A&gt; %&gt;N A ABS
22	synergy	synergy		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG	@&lt;P %NH N NOM SG
23	,	,
24	indicating	indicate		@-FMAINV %VA ING
25	that	that	pm:&gt;28	@CS %CS CS
26	this	this	det:&gt;27	@DN&gt; %&gt;N DET DEM SG
27	element	element	subj:&gt;28	@SUBJ %NH N NOM SG
28	is	be	obj:&gt;24	@+FMAINV %VA V PRES SG3
29	essential	essential	comp:&gt;28	@PCOMPL-S %NH A ABS
30	for	for	mod:&gt;29	@&lt;NOM %N&lt; PREP
31	MEF2	mef2	attr:&gt;32	@A&gt; %&gt;N N NOM SG
32	&amp;#8211;	&amp;#8211;	attr:&gt;33	@A&gt; %&gt;N N NOM SG
33	GATA-4	gata-4	attr:&gt;34	@A&gt; %&gt;N N NOM SG
34	cooperation	cooperation	pcomp:&gt;30	@&lt;P %NH N NOM SG
35	.     .
</fdg>
</example>
<example src="EMBO" no="4">
<text>
In contrast, transcriptional stimulation was abolished by further deletion of the C-terminal transactivation domain in the Pax5 mutants B8 and B9, whereas internal deletion of the conserved octapeptide motif (OP) or the partial homeodomain (HD) of Pax5 did not have any effect (Figure 3B).

</text>
       <arg n="0">further deletion of the C-terminal transactivation domain in the Pax5 mutants B8 and B9
</arg>
       <arg n="1">transcriptional stimulation
</arg>
<fdg>
1	In	in	cla:&gt;7	@ADVL %EH PREP
2	contrast	contrast	pcomp:&gt;1	@&lt;P %NH N NOM SG
3	,	,
4	transcriptional	transcriptional	attr:&gt;5	@A&gt; %&gt;N A ABS
5	stimulation	stimulation	subj:&gt;6	@SUBJ %NH N NOM SG
6	was	be	v-ch:&gt;7	@+FAUXV %AUX V PAST
7	abolished	abolish	main:&gt;0	@-FMAINV %VP EN
8	by	by	agt:&gt;7	@ADVL %EH PREP
9	further	further	det:&gt;10	@DN&gt; %&gt;N DET
10	deletion	deletion	pcomp:&gt;8	@&lt;P %NH N NOM SG
11	of	of	mod:&gt;10	@&lt;NOM-OF %N&lt; PREP
12	the	the	det:&gt;15	@DN&gt; %&gt;N DET
13	C-terminal	c-terminal	attr:&gt;14	@A&gt; %&gt;N A ABS
14	transactivation	transactivation	attr:&gt;15	@A&gt; %&gt;N N NOM SG
15	domain	domain	pcomp:&gt;11	@&lt;P %NH N NOM SG
16	in	in	mod:&gt;15	@&lt;NOM %N&lt; PREP
17	the	the	det:&gt;19	@DN&gt; %&gt;N DET
18	Pax5	pax5	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	mutants	mutant	pcomp:&gt;16	@&lt;P %NH N NOM PL
20	B8	b8	mod:&gt;19	@APP %NH N NOM SG
21	and	and		@CC %CC CC
22	B9	b9		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@&lt;P %NH N NOM SG
23	,	,
24	whereas	whereas	pm:&gt;46	@CS %CS CS
25	internal	internal	attr:&gt;26	@A&gt; %&gt;N A ABS
26	deletion	deletion	subj:&gt;44	@SUBJ %NH N NOM SG
27	of	of	mod:&gt;26	@&lt;NOM-OF %N&lt; PREP
28	the	the	det:&gt;31	@DN&gt; %&gt;N DET
29	conserved	conserved	attr:&gt;30	@A&gt; %&gt;N A ABS
30	octapeptide	octapeptide	attr:&gt;31	@A&gt; %&gt;N &lt;?&gt; N NOM SG
31	motif	motif	pcomp:&gt;27	@&lt;P %NH N NOM SG
32	(	(
33	OP	op	mod:&gt;31	@NH %NH N NOM SG
34	)	)
35	or	or	cc:&gt;31	@CC %CC CC
36	the	the	det:&gt;38	@DN&gt; %&gt;N DET
37	partial	partial	attr:&gt;38	@A&gt; %&gt;N A ABS
38	homeodomain	homeodomain	cc:&gt;31	@&lt;P %NH &lt;?&gt; N NOM SG
39	(	(
40	HD	hd	mod:&gt;38	@NH %NH ABBR NOM SG
41	)	)
42	of	of	mod:&gt;40	@&lt;NOM-OF %N&lt; PREP
43	Pax5	pax5	pcomp:&gt;42	@&lt;P %NH N NOM SG
44	did	do	v-ch:&gt;46	@+FAUXV %AUX V PAST
45	not	not	neg:&gt;44	@ADVL %EH NEG-PART
46	have	have	cnd:&gt;7	@-FMAINV %VA V INF
47	any	any	det:&gt;48	@DN&gt; %&gt;N DET
48	effect	effect	obj:&gt;46	@OBJ %NH N NOM SG
49	(	(
50	Figure	figure		@A&gt; %&gt;N N NOM SG
51	3B	3b	qua:&gt;46	@ADVL %EH NUM CARD
52	)	)
53	.     .
</fdg>
</example>
<example src="EMBO" no="5">
<text>
Groucho binding was, however, abolished by mutating a conserved phenylalanine of the eh1/GEH sequence to glutamic acid (Jimnez et al., 1999).

</text>
       <arg n="0">mutating a conserved phenylalanine of the eh1/GEH sequence to glutamic acid
</arg>
       <arg n="1">Groucho binding
</arg>
<fdg>
1	Groucho	groucho	attr:&gt;2	@A&gt; %&gt;N N NOM SG
2	binding	binding	subj:&gt;3	@SUBJ %NH N NOM SG
3	was	be	v-ch:&gt;7	@+FAUXV %AUX V PAST
4	,	,
5	however	however	meta:&gt;7	@ADVL %EH ADV WH
6	,	,
7	abolished	abolish		@-FMAINV %VP EN
8	by	by	man:&gt;7	@ADVL %EH PREP
9	mutating	mutate	pcomp:&gt;8	@&lt;P-FMAINV %VA ING
10	a	a	det:&gt;12	@DN&gt; %&gt;N DET SG
11	conserved	conserved	attr:&gt;12	@A&gt; %&gt;N A ABS
12	phenylalanine	phenylalanine	obj:&gt;9	@OBJ %NH &lt;?&gt; N NOM SG
13	of	of	mod:&gt;12	@&lt;NOM-OF %N&lt; PREP
14	the	the	det:&gt;15	@DN&gt; %&gt;N DET
15	eh1/GEH	eh1/geh	pcomp:&gt;13	@&lt;P %NH &lt;?&gt; N NOM SG
16	sequence	sequence		@+FMAINV %VA V PRES
17	to	to	ha:&gt;16	@ADVL %EH PREP
18	glutamic	glutamic	attr:&gt;19	@A&gt; %&gt;N A ABS
19	acid	acid	pcomp:&gt;17	@&lt;P %NH N NOM SG
20	(	(
21	Jiménez	jimenez	main:&gt;20	@APP %NH N NOM SG
22	et	et		@CC %CC CC
23	al.	al.		@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@&lt;P %NH ABBR NOM SG	@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG	@ADVL %EH ABBR NOM SG
24	,	,
25	1999	1999		@NH %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
26	)	)
27	.     .
</fdg>
</example>
</roleset>
</predicate>
</frameset>
